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ABSTRACT
Short oligonucleotides below 8–10 nt in length
adopt relatively simple structures. Accordingly,
they represent interesting and so far unexplored
lead compounds as molecular tools and, potentially,
for drug development as a rational improvement of
efficacy seem to be less complex than for other
classes of longer oligomeric nucleic acid. As a
‘proof of concept’, we describe the highly specific
binding of the hexanucleotide UCGUGU (Hex-S3)
to human immunodeficiency virus type 1 (HIV-1)
reverse transcriptase (RT) as a model target.
Ultraviolet (UV) cross-linking studies and competi-
tion experiments with primer/template substrates
and a RT-directed aptamer suggest site-specific
binding of Hex-S3 to the large subunit (p66) of the
viral enzyme. The affinity of 5.3 mM is related to
hexanucleotide-specific suppression of HIV-1 rep-
lication in human cells by up to three orders of
magnitude indicating that Hex-S3 exerts specific
and biologically relevant activity. Experimental evi-
dence described here further suggests a systematic
hexamer array-based search for new tools for
molecular biology and novel lead compounds in
nucleic acid-based drug development.
INTRODUCTION
The chemical nature of nucleic acids provides the possibility
for a variety of speciﬁc, biologically relevant interactions
with different classes of biomolecules. Historically, this has
been realized by aptamers which usually consist of 40–
50 nt or more and which require speciﬁc secondary and
tertiary folding for full activity. Aptamers have been selected
from large sequence spaces to bind almost any kind of
chemical entities including small metabolites, such as
amino acids, nucleotides or antibiotics, as well as macro-
molecules, such as proteins or nucleic acids (1–4). Even
against complex targets, such as the protozoan parasite
Trypanosoma Brucei (5), the human red blood cell ghost
(6), or the intact Rous sarcoma virus (RSV) (7) speciﬁc
aptamers have been successfully selected. In contrast, one
may consider that a sufﬁcient number of contacts can be
made to provide strong and speciﬁc binding of mono- and
dinucleotides to nucleoside- and nucleotide-binding proteins.
This is particularly true for some chemically modiﬁed nucleo-
sides, which comprise an established class of approved
drugs for the therapeutic clinical use (8) while oligomeric
candidates are still on the way to this point.
As an extension of mono- and dinucleotides it is attractive
to speculate about sequence-speciﬁc binding of very short
heterooligonucleotides to a given target protein. In this
case, target speciﬁcity might not occur through a combination
of shape and sequence-speciﬁc interactions but rather con-
tacts along the quasi linear oligonucleotide molecule. In
this context, we ask whether speciﬁc interactions between
very short non-structured oligonucleotides and a protein tar-
get do occur, and if so, the binding afﬁnity is strong enough
to be biologically relevant. As a model system for addressing
this hypothesis we chose hexameric oligonucleotides and the
reverse transcriptase (RT) of the human immunodeﬁciency
virus type 1 (HIV-1). Hexanucleotides as opposed to pentanu-
cleotides or heptanucleotides were chosen, because the
sequence space of 4
6 (4096) seemed to be most appropriate
to look at this concept. HIV-1 RT was chosen based on the
following considerations: (i) the 3D structure is known allow-
ing for detailed modeling studies, (ii) binding of high-afﬁnity
aptamers shows that, in principle, RT interacts with non-
substrate like nucleic acids at sites that are different from
the primer/template binding site, (iii) in technical terms,
highly pure and active enzyme can be obtained in large
amounts (9) and (iv) the availability of appropriate cell
based assays for testing potential inhibitors.
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Oligonucleotides
All oligonucleotides used in this study were purchased from a
commercial supplier (IBA, Go ¨ttingen, Germany). Their con-
centration was routinely determined by the ultraviolet (UV)
absorption spectroscopy and the individual extinction coefﬁ-
cients. The integrity was controlled applying denaturing
PAGE [20% (w/v) acrylamide, 7 M urea] followed by stain-
ing with Stains-All (Sigma–Aldrich, Deisenhofen, Germany).
Oligonucleotides were 50 end-labeled with T4 polynucleotide
kinase (MBI Fermentas, St Leon-Rot, Germany). Brieﬂy,
10 pmol of oligonucleotide were incubated with poly-
nucleotide kinase and 30 mCi of [g-
32P]ATP (PerkinElmer,
Boston, MA) for 30 min at 37 C. Reactions were stopped
by heating the samples for 5 min at 95 C. Labeled oligo-
nucleotides were analyzed by using a PhosphorImager after
denaturing PAGE [20% (w/v) acrylamide, 7 M urea].
Proteins
Recombinant heterodimeric wild-type HIV-1, HIV-2, equine
infectious anemia virus (EIAV) RT and the p51 subunit of
HIV-1 RT were expressed in Escherichia coli and puriﬁed
as described before (9–11). Enzyme concentrations were
routinely determined using an extinction coefﬁcient at
280 nm of 260450 (HIV-1 RT), 238150 (HIV-2 RT),
223180 (EIAV RT) and 124180 M
 1 cm
 1 (HIV-1 p51).
The puriﬁed RTs were free of nuclease contamination. T7
RNA polymerase (12) was expressed in E.coli and puriﬁed
as described (13,14). Enzyme concentration was routinely
determined using an extinction coefﬁcient at 280 nm of
140000 M
 1 cm
 1. BSA was purchased from Promega
(Mannheim, Germany).
Combinatorial screening of a random pool of
hexadeoxyribonucleotides for binding to HIV-1 RT
A random library of hexanucleotides (10 nM) was mixed with
HIV-1 RT (10 mM) and incubated at 37 C for 10 min in buf-
fer containing 50 mM Tris–HCl (pH 8.0), 50 mM KCl, 5 mM
MgCl2 in a ﬁnal volume of 20 ml. The mixture was soaked
through a nitro-cellulose ﬁlter BA85 (Schleicher & Schuell,
Dassel, Germany) and rinsed with 3 ml of binding buffer.
The hexamers retained on the ﬁlter were extracted from the
nitro-cellulose by heating for 10 min at 95 C in 1 ml of
water. The eluted hexanucleotides were subjected to
poly(C) extension of the 30 termini for 10 min at 37 C
using terminal deoxynucleotidyl transferase (MBI Fermentas,
St Leon-Rot, Germany). Tailed products were then precipi-
tated in ethanol and ligated at their 50 termini with a primer
PA (TGCAGGCTCGAGTTAATTAACTGA) by T4-RNA
ligase (MBI Fermentas, St Leon-Rot, Germany). Reactions
were stopped by heating at 95 C for 5 min. Ligated products
were precipitated in ethanol and ampliﬁed by PCR in the
presence of Taq polymerase (New England Biolabs, Ipswich,
MA) and primers PA, PB (TGTATTGCGGCCGCTGATC-
TAGA) and adaptor-PB [TGTATTGCGGCC GCTGATCTA-
GA(G)14]. PCR products were subsequently cloned in the
pCRII-TOPO vector (Invitrogen, Karlsruhez, Germany) and
sequenced.
It should be noted that our attempts to use the RNA
analogs, i.e. hexaribonucleotides as substrates for ter-
minal deoxynucleotidyl transferase, poly(A)polymerase, and
T4-RNA ligase showed extremely little product or failed.
We suspect that very short RNAs are poor substrates for
those enzymes.
Filter binding assay
Typically, radiolabeled oligonucleotides (1 nM) and target
proteins (5–25 mM) were incubated in 30 ml of binding buffer
[50 mM Tris–HCl (pH 8.0), 5 mM KCl, 5 mM MgCl2 and
1 mM DTT] for 2 min at 25 C. An aliquot (10 ml) of this
mixture was ﬁltered under suction through a prewet nitro-
cellulose ﬁlter BA85 (Schleicher & Schuell, Dassel,
Germany) and rinsed with 3 ml of binding buffer. Radio-
activity retained on the ﬁlters was measured by scintillation
counting (PerkinElmer, Boston, MA).
UV cross-linking
An amount of 250 pmol of HIV-1 RT and of 100 fmol
32P-labeled 4-thio U-modiﬁed Hex-S3R (position 4) were
pre-incubated in binding buffer (see above) for 2 min at
25 C. Samples were then transferred on a piece of Paraﬁlm,
placed on ice and irradiated for 20 min at 366 nm using a
hand-held ﬂuotest lamp (Heraeus, Hanau, Germany), fol-
lowed by heating for 5 min at 95 Ci n1 · Laemmli loading
buffer and resolved by 12% SDS–PAGE. Gels were stained
with Coomassie blue, dried and exposed to a PhosphorImager
screen.
CNBr cleavage of HIV-1 RT tagged
with
32P-labeled 4-thio U-modified Hex-S3R
HIV-1 RT cross-linked to
32P-labeled 4-thio U-modiﬁed Hex-
S3R was precipitated by 20% (w/v) trichloroacetic acid
(TCA), followed by a washing with acetone. The pellet was
then air-dried and dissolved in 100 ml formic acid (70%) con-
taining 3.5 g/l cyanbromide (CNBr). Cleavage reaction was
performed at room temperature for 24 h. Formic acid and
CNBr were removed by centrifugal-lyophilization in a
speed-vac. The pellet was dissolved in 50 mM Tris–HCl
(pH 8.0) buffer, heated 5 min at 95 Ci n1 · Laemmli loading
buffer and resolved by SDS–PAGE [10–20% (w/v) linear
gradient]. Gels were stained with Coomassie blue, dried
and exposed to a PhosphorImager screen. All reagents were
purchased from Sigma–Aldrich (Deisenhofen, Germany).
Modeling and docking studies
Rigid-body docking studies of HIV-1 RT (Brookhaven Pro-
tein Data Bank accession nos: 1HMV, 1RTH, 1RTD and
1HVU) and Hex-S3 were performed with the program Hex
4.2 (15). Molecular graphics images were produced using
the UCSF Chimera package from the Computer Graphics
Laboratory, University of California, San Francisco (16).
Virus replication assay
Hexamers were co-transfected by calciumphosphate
co-precipitation with pGJ3-Luci and pczVSV-G in 10
6
293T cells as described in detail recently (17). In brief,
5632 Nucleic Acids Research, 2006, Vol. 34, No. 1960 min thereafter medium was exchanged and the cells were
incubated for 40 h followed by ﬁltration (0.45 mm). The
cleared supernatant (0.2–0.3 ng of p24 core antigen per ml)
was used to infect a number of 2 · 10
4 293 cells in a 96-
well format for 24 h in the presence of polybrene (8 mg/
ml). Cell viability was monitored by the conversion of ﬂuo-
rescein diacetate (FDA) (18) and the expression of luciferase
was measured in a Fluoroskan Ascent  FL (Thermo Labsys-
tems, Dreieich, Germany) after addition of 50 ml of the fol-
lowing buffer: 28 mM Tricine (pH 7.8), 500 mM ATP,
250 mM coenzyme A, 250 mM luciferin, 33 mM DTT,
200 mM EDTA, 15 mM MgSO4, 1.5% (v/v) Triton X-100
and 5% (v/v) glycerol. All reagents were purchased from
Sigma–Aldrich (Deisenhofen, Germany).
RESULTS AND DISCUSSION
Binding of hexanucleotides to HIV-1 RT
First, we performed a combinatorial selection approach in
solution at physiological ionic strength and temperature to
search for DNA hexanucleotides binding to RT. Sequence
analysis of a number of 35 cloned hexamers revealed seven
different species with divergent nucleotide sequences (data
not shown) which is consistent with the view that at the
experimental conditions and stringency of selection used
here a number of divergent hexanucleotides can bind at simi-
lar strength. The best-binding species in this screening proce-
dure included Hex-S1 (CGACCG) and Hex-S3 (TCGTGT)
(A. Mescalchin and W. Wu ¨nsche, unpublished data). To fur-
ther analyze their interaction with RT a ﬁlter binding assay
was used (19). As positive controls we included a well-
characterized high-afﬁnity RNA aptamer (19–21), a DNA
aptamer (22) and a DNA/DNA primer/template substrate
(23). As negative controls we included hexanucleotides
(Hex-0, Hex-1) chosen from the group of non-binders.
Since we used DNA as well as RNA backbones as controls
in this study, we further decided to investigate Hex-S1,
Hex-S3 and Hex-S4 and their hexameric controls as RNA
(lower script ‘R’) and DNA (lower script ‘D’) in ﬁlter binding
assays (Figure 1A). Here we ﬁnd no binding of the negative
controls Hex-0 and Hex-1 but measurable binding of all
selected hexamers. The RT-directed DNA aptamer was set
100 arbitrary units binding in Figure 1A. Remarkably, all
RNA and DNA versions of the same sequence show compa-
rable binding to RT (Figure 1A). Since Hex-S3 shows stron-
gest binding, we performed a more detailed analysis with this
species. Its binding afﬁnity to RT was reﬂected by an appar-
ent Kd of 5.3 (±0.5) mM (Figure 1B). By stepwise replacing
the original nucleotides of the adenosine-free Hex-S3R for
an adenosine, important contributions of the central positions
3–5 opposed to the terminal nucleotides at positions 1, 2 and
6 could be identiﬁed (Figure 1C). This clearly indicates that
binding afﬁnity and speciﬁcity require bases in the central
portion of the molecule but not necessarily at the termini.
In order to test whether this is also true for the hexameric
backbone, i.e. simply a phosphodiester/sugar backbone, we
measured binding of the two 50- and 30-shortened pentameric
derivatives of Hex-S3R. Under the experimental conditions
used here we did not observe any signiﬁcant binding of
both Hex-S3R-derived pentanucleotides and shortened
versions thereof (CGTGT and TCGTG, Supplementary
Figure 1a). From those observations we conclude that a
hexameric backbone and the stretch GTG are necessary for
efﬁcient binding of Hex-S3 to RT.
Binding of derivatives of Hex-S3 to RT
Next we analyzed the effect of chemical modiﬁcations of
Hex-S3R on binding to RT. The similar binding strength of
the DNA and the RNA derivatives Hex-S3 (Figure 1A) sug-
gests that the 20-OH does not substantially contribute to bind-
ing. Further binding studies with several derivatives of Hex-
S3 revealed that the 50-phosphate is not important for binding
whereas fully 20-OMe derivatives and a LNA derivative at
position 1 show decreased binding afﬁnity (Table 1). Phos-
phorothioate derivatives of Hex-S1, Hex-S3, Hex-0 and
Hex-1 all show increased binding to RT accompanied by a
dramatic loss of sequence-speciﬁcity (Table 1). Moreover, a
4-thio U at position 4 of Hex-S3 used later for UV cross-
linking studies had no effect on binding (Table 1).
It is noteworthy that all possible eight derivatives of Hex-
S3 elongated by 1 nt at either terminus show an  3-fold
stronger binding to RT while still being speciﬁc for the target,
i.e. for HIV-1 RT versus HIV-2 RT (Supplementary
Figure 1b). However, extension to a 12mer or 18mer is accom-
panied, besides further increase in afﬁnity, by a progressively
increased loss of speciﬁcity (Supplementary Figure 1c). This
observation is consistent with the view that the binding mode
of Hex-S3, i.e. binding to a speciﬁc pocket on the protein
surface, changes at increasing chain length in such a way
that it resembles natural substrates of this polymerase.
Site-specific binding of Hex-S3 to RT
A speciﬁc interaction of Hex-S3R with HIV-1 RT, as implied
by the ﬁndings given above, would suggest a deﬁned binding
site on the protein. In order to examine this possibility we
performed UV cross-linking with a
32P-radiolabeled 4-
thio-uridine derivative of Hex-S3R followed by CNBr
treatment of RT. This experiment clearly shows that only
the large subunit p66 is cross-linked (Figure 1D) and of the
fragments obtained, speciﬁcally two are labeled. The two
fragments were isolated from the gel and their N-terminal
amino acid sequence was determined. One of them (42–183
amino acid, indicated by green color in Figure 1E) carries
approximately one-third and the second one (231–356
amino acid, indicated by red color in Figure 1E) about two-
thirds of the label (Figure 1D). Further information on the
binding site of Hex-S3R comes from competition experiments
with a 18/36mer DNA/DNA primer/template (23), a RNA
aptamer (19,20), as well as the non-nucleoside inhibitor
S-TIBO (24). TIBO has been shown to stabilize an open
conformation of RT, i.e. rotation of the p66 thumb domain
of  30–40  generating a large nucleic acid binding site
(25,26), whereas the RNA aptamer induces a closed confor-
mation (20,26). These competition studies are surprising in
the sense that primer/template and aptamer compete for
hexamer binding but not vice versa. S-TIBO increased
hexanucleotide binding by  2-fold (data not shown). Taking
these experimentally derived constraints into consideration,
we performed rigid-body docking studies of HIV-1 RT and
Hex-S3 (Figure 1E, Supplementary Figure 2). According to
Nucleic Acids Research, 2006, Vol. 34, No. 19 5633this speculative model, Hex-S3 binds the p66 subunit at the
bottom of the thumb domain pointing towards the nucleic
acid binding cleft of the viral polymerase. Binding of this
hexanucleotide ligand requires the thumb domain to be in
an upright position. Furthermore, the interaction of RT with
natural primer/template substrates is not hampered, whereas
access of Hex-S3 to its binding site is sterically blocked in
the presence of substrate. This would explain the results of
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position of Hex-S3 for binding to RT. An adenosine was introduced at each of the positions. (D) Site-specific binding of Hex-S3R modified by a 4-thio-uridine at
position 4 to RT as shown by UV cross-linking. Left panel, Coomassie blue-stained gel; middle panel, autoradiograph; right panel, overlay. (E) The 3D model
of the binding site of RT for Hex-S3 based on docking studies and the constraints explained in the text. Color code: yellow, Hex-S3; green, CNBr fragment
(42–183 amino acid); red, CNBr fragment (231–356 amino acid); blue, remaining portions of the large subunit p66; gray, small subunit p51. (F) Protein target
specificity of Hex-S3.
5634 Nucleic Acids Research, 2006, Vol. 34, No. 19the competition experiments described above (Supplementary
Figure 2).
Protein target specificity of Hex-S3
So far, we showed that hexanucleotide binding to RT is
highly speciﬁc for the nucleotide sequence. Next we investi-
gated whether Hex-S3 speciﬁcally binds to HIV-1 RT as a
target. For this matter, ﬁlter binding assays were performed
with (i) the small subunit p51 of HIV-1 RT, (ii) HIV-2 RT,
which is highly homologous to the HIV-1 RT (60% amino
acid identity plus 13% amino acid homology), (iii) EIAV
RT, (iv) T7 RNA polymerase and (v) BSA (Figure 1F).
The weak or absent binding of Hex-S3 to all of those control
proteins suggests a high degree of target speciﬁcity which is
particularly striking when considering the close structural and
functional relationship among the polymerases tested here,
particularly the RT of HIV-2 (27).
Biological activity of Hex-S3R in a cell
culture model for HIV-1 replication
Regarding the development of potential hexanucleotide-
derived drugs, we analyzed whether Hex-S3 is able to exert
biological effects, i.e. to negatively interfere with the replica-
tion of HIV-1 in human cells by using a recombinant proviral
construct as described in detail elsewhere (17). In this setup,
packaging cells are transfected with a luciferase-harboring
defective HIV-1 genome and plasmid-encoded packaging
functions which give rise to the release of infectious recom-
binant particles that are subsequently used to infect recipient
cells in which luciferase gene expression monitors infectivity.
In this system, we co-transfected hexanucleotides in the ﬁrst
step and observed a strong, concentration-dependent decrease
of luciferase activity in newly infected 293T cells using Hex-
S3 but not in case of the control Hex-1 (Figure 2). Regarding
an assessment of the particular step of the viral life cycle that
could be affected by Hex-S3, we performed a number of
additional experiments. In summary we ﬁnd the following:
(i) if one co-transfects hexamers together with packaging
functions of HIV-1 using the single-round replication systems
described, then clearly less viral particles, as monitored by a
p24-speciﬁc enzyme-linked immunosorbent assay (ELISA),
are released from transfected cells when Hex-S3 is used ver-
sus a control hexamer (Hex-1). In spite of this, when equal
amounts of these viruses (produced in the presence of Hex-
S3 or a control hexamer) are subsequently applied to infect
293T cells, there is no difference between the observed
reporter gene activity. This strongly suggests that the Hex-
S3-speciﬁc inhibitory step occurs in packaging cells rather
than during early steps of infection. In depth in vitro bio-
chemical analyses of the polymerase activity of RT in the
presence of either hexamers does not indicate a difference
that could explain the observed dose-dependent inhibition
of HIV-1 in cell culture. Those analyses included the follow-
ing characteristics of RT: ﬁdelity, processivity, RNase H
activity and DNA- and RNA-dependent DNA polymerase
activity (data not shown). All of the experimental data, how-
ever, are compatible with the view that the packaging efﬁci-
ency of HIV-1 in the presence of Hex-S3 is substantially
suppressed in a concentration-dependent fashion. This view
has been described more in detail recently for the inhibition
of HIV-1 by a RT-directed RNA aptamer (21). Several sce-
narios are feasible. To address but a few it is quite possible,
that a compound, which does not interfere with the enzymatic
activities of the viral polymerase blocks assembly of infec-
tious particles simply by physical interaction with RT.
There are mutations of RT known supporting this view
(28,29). Alternatively, selective packaging of the tRNA
primer could be affected (30).
Since the viral target is RT in this study, we investigated
the well-established nucleoside inhibitor AZT and the non-
nucleoside inhibitor S-TIBO in the same cell system. Both
suppress RT by different modes of action, however, they
show IC50 values here (AZT, 79 nM; S-TIBO, 101 nM; Sup-
plementary Figure 3) that are somewhat lower when com-
pared with IC50 values in infectious test systems. If one
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Figure 2. Biological activity of Hex-S3R in a cell culture model for HIV-1
replication. Briefly, in a first step, packaging 293T cells are co-transfected
with a luciferase-harboring defective HIV-1 genome and plasmid-encoded
packaging functions (see Materials and Methods section). Released infectious
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Table 1. Percentage of binding of derivatives of hexanucleotides to HIV-1 or
HIV-2 RTs at 1 mM protein concentration
Name HIV-1 RT HIV-2 RT
Hex-0D 0.3 ± 0.0 nd
Hex-1D 0.4 ± 0.1 nd
Hex-S1D 5.8 ± 0.6 nd
Hex-S3D 8.1 ± 1.0 nd
4-thioU-Hex-S3R 9.8 ± 0.5 nd
Hex-0D -20OMe 2.0 ± 0.0 nd
Hex-1D -20OMe 0.9 ± 0.2 nd
Hex-S1D -20OMe 0.5 ± 0.1 nd
Hex-S3D -2 0OMe 2.0 ± 0.1 nd
Hex-S3D -LNA 4.3 ± 0.4 nd
Hex-0D -PS 19.1 ± 2.1 10.6 ± 1.9
Hex-1D -PS 20.8 ± 2.9 12.9 ± 0.7
Hex-S1D -PS 18.3 ± 6.0 6.6 ± 1.7
Hex-S3D -PS 52.8 ± 9.8 24.9 ± 3.6
Abbreviations: -20OMe, 20-O-methyl, fully modified; -LNA, locked nucleic
acid, 1 nt modified at 50-terminus; -PS, phosphorothioate, fully modified;
nd, not determined. Indicated are mean value ± standard deviation.
Nucleic Acids Research, 2006, Vol. 34, No. 19 5635considers Hex-S3 as a ‘lead’ compound then the gap between
the effective drugs AZT and S-TIBO and Hex-S3 [IC50 ¼ 1.8
(±0.2 mM), data not shown] is surprisingly narrow.
Stability of hexanucleotides versus
Hex-S3-derived 24mers
Further, we tested the serum stability of Hex-S3 and of chemi-
cally modiﬁed versions including the phosphorothioate-,
LNA- and 20-OMe derivatives and compared it with
oligonucleotides of common length of 24 nt (data not
shown). All chemically modiﬁed hexamers behave as one
would derive from well-known data of longer ones. It is note-
worthy, however, that the unmodiﬁed hexamers show an
increased nuclease resistance when compared with 24mers,
which is particularly true for the RNA version (Supplementary
Figure 4).
Binding of RT to hexamers covalently
attached to a trial array
To test whether an array-based approach is feasible we stud-
ied the differential binding of HIV-1 RT to hexamer species
(for sequences see Figure 1A), which have been covalently
attached via linkers to a solid surface. In order to monitor
binding of RT we used a site-directed ﬂuorescently labeled
RT (p66/p51
K281CAlexa
488) which was shown earlier to pre-
serve all enzymatic activities (19,26,31). This experiment
shows strong binding of a RT-directed 49mer DNA aptamer
(22) and a substrate like 45mer single-stranded DNA as well
as binding of the hexamers Hex-S1D and Hex-S3D (Figure 3),
which is consistent with binding data of Hex-S3 observed in
solution (Figure 1A). A similarly clear consistency is
observed in the use of the non-binders Hex-0 and Hex-1
(Figure 3). When Alexa
488 was introduced at amino acid
position 287 of the p66 subunit of RT (p66
K287CAlexa
488/
p51) instead of position 281 of the p51 subunit, the binding
behavior was identical with the above observations indicating
that these ﬁndings are not affected by the ﬂuorescent moiety
of RT. The ﬂuorescence signals are speciﬁc for the linker-
bound oligonucleotides since nuclease treatment prior to the
binding of RT abolishes ﬂuorescence on the solid matrix
and linker alone does not give rise to a signal as well (data
not shown).
These ﬁndings strongly suggest an array-based approach to
test complete sequence spaces of very short oligonucleotides,
e.g. the one of 1024 pentanucleotides or the one of 4096
hexanucleotides, and in turn to identify speciﬁcally and sufﬁ-
ciently tight-binding species with a given target which would
be of substantial interest for basic research and, as a lead, for
biomedical and pharmacological purposes including drug
development.
CONCLUSION
Taken together, this work strongly suggests that hexa-
nucleotides may be considered as an as yet unexplored
class of compounds with a number of highly promising char-
acteristics for drug development. Based on the results shown
for Hex-S3, we propose hexanucleotides in general may
provide high speciﬁcity and sufﬁcient binding afﬁnity for a
given target and, thus, represent attractive lead compounds.
It is noteworthy that binding of a protein target by short
oligonucleotides was described for the integrase (32,33) and
the envelope protein gp120 of the HIV-1. In case of gp120
this was related to inhibition of gp120-mediated cell fusion
(34). However, binding afﬁnity in those cases was not due
to speciﬁc primary nucleotide sequences but rather to the
presence of an acridine moiety (33), a 6-oxo-cytosine residue,
or the ability of phosphorothioate-modiﬁed oligonucleotides
to form higher quadruplex structures (34).
Several strategies can be envisaged to further increase the
binding afﬁnity and, hence, the biological activity of Hex-S3.
First, rational drug design in the classical sense could be
based on docking studies with the known 3D structure of
HIV-1 RT. Second, saturation transfer difference (STD)
NMR (35) could be exploited to determine the critical resi-
dues for binding of Hex-S3 to RT, which in turn can be
chemically modiﬁed potentially leading to increased binding
strength. Third, systematic pools of unmodiﬁed or chemically
modiﬁed hexanucleotides can be tested for speciﬁc binding to
RT or any other target of interest. This may exploit the array-
based technology, brieﬂy described above. This enables one,
in principle, to perform an extremely rapid and systematic
search for hexamers that bind to a given target sufﬁciently
speciﬁc and tight, thereby representing a ﬁrst lead.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR online.
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Figure 3. Binding of RT to hexamers and controls covalently attached to
a trial array. Oligonucleotides were printed such that they were positioned at
the terminus of a 40 atoms tether covalently bound to the matrix. The density
was  1 fmol of oligonucleotide per spot (top panel). The arrays were
incubated with fluorescently labeled RT, washed and fluorescence intensity
was measured with a fluorescence imager. A quantification of representative
experimental data is shown in the bottom panel and the corresponding Kd
values in solution are shown on top of the bars. The nucleotide sequence of
the DNA 45mer is d(T20CTGTACAGGTAGCAATGGCAGGTGC).
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